'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery' (RISK)

September 24, 2020 updated by: JuttedeVries, Leiden University
This is a prospective single- center observational study in the Leiden University Medical Center in approximately 250 children (<12 years) undergoing elective cardiac surgery, for congenital heart disease. The parents/guardians of the children will be asked to fill out a questionnaire, to asses respiratory symptoms in the last weeks, before the operation of their child. In the operating theatre, a nasopharyngeal swab will collected. Clinical data will be collected daily during paediatric intensive care admission, and date of discharge from paediatric intensive care unit and from hospital are recorded. If children are still intubated at day 4 a second nasopharyngeal swab and residual blood will be collected. The samples will be tested for rhinovirus with a polymerase chain reaction. Main study parameter is the paediatric intensive care unit length of stay in per-operative rhinovirus -positive compared to rhinovirus-negative patients.

Study Overview

Detailed Description

Rationale:

Respiratory infections are considered to carry a potential risk of adverse events in children undergoing surgery.

Rhinovirus is a common cause of respiratory infections and congenital heart disease is a risk factor for severe rhinovirus infection. However, we do not know what the impact of clinical or subclinical rhinovirus infections is on postoperative course following congenital heart surgery in children.

Based on our clinical experience, one case-controlled study , and a case reported in the literature, we hypothesize that paediatric patients with per-operative rhinovirus positive Polymerase Chain Reaction (PCR) testing have a longer paediatric intensive care unit (PICU) admission , compared to children who test negative.

Objectives:

Primary: To identify whether PCR-proven rhinovirus is a risk factor for prolonged PICU admission in children undergoing cardiac surgery.

Secondary: to develop a preoperative algorithm to identify children with increased risk for prolonged PICU admission after cardiac surgery.

Study design:

This is a prospective single-center observational cohort study in the Leiden University Medical Center (LUMC).

Methods Parents of the selected patients will receive the information folder and a questionnaire by mail (asking for signs and symptoms of current and/or recent respiratory infections) when they receive the letter with the date of admission and operation.

On the day of admission (day -1) all (parents of) children admitted for cardiac surgery will be asked to participate in this study and fill out a written informed consent.

At day 0, the operation day, in the operating theatre a nasopharyngeal swab will be collected following anaesthetic induction and tested for rhinovirus. All clinicians will be blinded for the PCR results and will only be made known to the investigator from the virology department.

Clinical and laboratory data will be collected for all patients until discharge from the hospital. Of all the patients still on mechanical ventilation at day 4, an additional nasopharyngeal swab will be sampled and scavenge samples blood will be requested at the chemical laboratory if available. Rhinovirus PCR will be performed on nasopharyngeal swab and blood to determine shedding and viremia.

Residual blood (for infection parameters) will be collected at three time points: after induction of anaesthesia, directly after operation at PICU admission and at day four (4) when the patient is still on ventilator support.

Study Type

Observational

Enrollment (Actual)

166

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leiden, Netherlands
        • Leiden University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Children (<12 year) with a congenital heart disease undergoing elective cardiac surgery

Description

Inclusion Criteria:

  • Children (<12 year) with a congenital heart disease undergoing elective cardiac surgery
  • Written informed consent by parents or guardian

Exclusion Criteria:

  • No informed consent from one of the parents (or the legal representative if applicable)
  • Anaesthesiologist or cardiopulmonary surgeon postpones surgery based on routine hospital screening
  • Emergency surgery
  • Pre-operative admission to the neonatology department
  • Children not admitted to the intensive care unit after cardiac surgery
  • Children undergoing a second cardiac operation during the same intensive care stay
  • Children with duct-dependent physiology who remain prostaglandin-dependent after the heart operation (they will be excluded because they will certainly have a prolonged PICU LOS regardless of a possible rhinovirus infection). For example: hypoplastic left heart syndrome following pulmonary artery banding who will remain on prostaglandins until the next staged operation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
children undergoing cardiac surgery
paediatric patients with a congenital heart disease undergoing elective cardiac surgery
rhinovirus PCR on a nasopharyngeal swab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post-operative PICU length of stay
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
rhinovirus PCR positive compared to rhinovirus negative patients
participants will be followed for the duration of PICU stay, an expected average of 3,8 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Duration of ventilatory support
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
mean airway pressure
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
FiO2
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
peak inspiratory pressure (maximum values)
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
positive end expiratory pressure (maximum values)
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
Antibiotic free days (alive at PICU discharge)
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
Need of inotropes (inotrope score)
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
CRP
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
Leukocytes
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
Hospital length of stay
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days
Any secondary infection (bacterial, viral and parasitic infections)
Time Frame: participants will be followed for the duration of PICU stay, an expected average of 3,8 days
participants will be followed for the duration of PICU stay, an expected average of 3,8 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anneloes L Klink, Msc, Leiden University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Actual)

June 1, 2018

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

April 30, 2015

First Submitted That Met QC Criteria

May 5, 2015

First Posted (Estimate)

May 8, 2015

Study Record Updates

Last Update Posted (Actual)

September 25, 2020

Last Update Submitted That Met QC Criteria

September 24, 2020

Last Verified

September 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Congenital Heart Disease

Clinical Trials on rhinovirus diagnostics

3
Subscribe